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ABSTRACT 
In present study describe the development of new method and parameter which will be considered during method development and validation. 
Article give brief idea for a simple, sensitive, precise and accurate High-performance thin-layer chromatographic method for simultaneous 
determination of Ritonavir and Atazanavir in their combined tablet dosage form has been developed, validated and used for determination of 
the compounds in commercial pharmaceutical products. Chromatographic separation will be achieved on different column like C8,  C18, etc. 
used as the stationary phase and different mobile phase.  
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1. INTRODUCTION 
Atazanavir Sulphate Methyl is a Antiretroviral drug N- [(1S)-
1-{ [(2S,3S) - 3 - hydroxy-4- [(2S)-2- [(methoxycarbonyl) 
amino] -3, 3-dimethyl-N'-{[4-(pyridin-2-yl)phenyl]methyl} 
butanehydrazido]-1- phenylbutan-2-yl] carbamoyl}-2, 2 - 
dimethyl propyl] carbamate sulphate is a azapeptide HIV-1 
protease inhibitor. The compound selectively inhibits the 
virus-specific processing of viral Gag and Gag-Pol 
polyproteins in HIV-1 infected cells, thus preventing 
formation of mature virions. 1 
 
Figure 1: chemical structure of Atazanavir Sulphate 
Ritonavir is a Antiretroviral drug 1,3-thiazol-5-ylmethyl N-
[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2{[methyl({[2-
(propan-2-yl)-1,3-tiazole-4-
yl]methyl})carbamoyl]amino}butane mido]-1,6-diphenyl 
hexan-2-yl] carbamate. Ritonavir inhibits the HIV viral 
protease enzyme. This prevents cleavage of the gag-pol 
polyprotein and, therefore, improper viral assembly results. 
This subsequently results in noninfectious, immature viral 
particles. 2 
 
Figure 2: chemical structure of Ritonavir 
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methods reported for the simultaneous estimation of 
Atazanavir and Ritonavir gives out information that there are 
few separate methods reported for the quantitative 
estimation of Atazanavir sulfate in bulk, pharmaceutical 
dosage forms and in plasma by HPLC, likewise a very few 
methods have been reported for the quantitative estimation 
of Ritonavir by HPLC but till date no method has been 
reported for the simultaneous quantitative estimation of 
Atazanavir and Ritonavir by HPLC [3-8]. There is just one 
spectrophotometric method reported for the simultaneous 
estimation of Atazanavir sulfate and Ritonavir in tablets. The 
present developed method was used determine the 
Atazanavir and Ritonavir present in the formulation and 
method validated according to the ICH guidelines. 3 
2. INTRODUCTION TO DRUG ANALYSIS  
Analytical chemistry is a branch of chemistry that 
determines the nature and identity of a substance and its 
composition. In the early twentieth century there were only 
four accepted branches of chemistry namely, organic 
chemistry, inorganic chemistry, physical chemistry and 
biochemistry. Its importance grew, and in the process, 
absorbed techniques and skills from all other four branches 
so by the 1950s, analytical chemistry was finally accepted as 
a branch of chemistry in its own right. 4 
The ability to provide timely, accurate, and reliable data is 
central to the discovery, development, and manufacture of 
pharmaceuticals. Analytical data are used to screen potential 
drug candidates, aid in the development of drug synthesis, 
support formulation studies, monitor the stability of bulk 
pharmaceuticals and formulated products, and test final 
products for release. The quality of analytical data is a key 
factor in the success of a drug development program. 5 
3. INTRODUCTION TO HPLC 
HPLC originally referred to the fact that high pressure was 
needed to generate the flow required for liquid 
chromatography in packed columns. In the beginning, 
instrument components only had the capability of generating 
pressures of 500psi (35 bar). This was called High Pressure 
Liquid Chromatography (HPLC). 6 
3.1 Instrumentation
 
 
 
Figure 3: Schematic Diagram of HPLC Instrument 
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4. INTRODUCTION TO METHOD DEVELOPMENT & 
VALIDATION 
Method development and optimization in liquid 
chromatography is an attractive field of research for 
academia and industry. Complex mixtures or samples 
required systematic method development involving accurate 
modeling of the retention behavior of the analyte.  
4.1   Critical steps for HPLC method development 7 
 
 
Information on a sample, define separation goals 
 
Need for special HPLC procedure, Sample pretreatment, etc 
 
Choose Detector and detector settings 
 
Choose LC Method, preliminary runs, estimate best separation conditions 
 
Optimize separation conditions 
 
Check for problems or requirements for special procedure 
 
Recover purified material, qualitative Calibration, Quantitative Method 
 
Validate Method for released routine laboratory 
 
 
Table 1: Preferred experimental conditions for the initial HPLC run 
Separation variable Initial condition 
Column 
 Dimensions (length, diameter) 
 Particle size  
Stationary phase  
 
150 × 4.6mm 
5μm(3.5μm alternatively) 
C8 or C18  
Mobile phase  
Solvent A and B  
% of strong solvent  
Buffer (compound, pH, and conc.) 
 pH range  
Additives (e.g. Ion pair reagent, amine modifier) 
 
Buffer- Acetonitrile  
80-100%  
25mM Potassium phosphate 
 2.0 < 3.0  
Do not use initially  
Flow rate 1.5-2.0 ml/min.  
Temperature 350-450 C.  
Sample size  
Volume  
Weight  
 
< 25μl 
 < 100μg 
 
 
4.2 Analytical Method Validation Parameters  
Before performing validation of analytical method it is 
necessary to understand the validation parameters. The 
various Performance parameters, which are addressed in a 
validation exercise, are grouped as follows. 8
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       Figure 4: Method Validation Parameters as per USP 
and ICH 
5. PARAMETER FOR METHOD VALIDATION 
5.1  Selectivity and Specificity:  
The selectivity of an analytical method is its ability to 
measure accurately and specifically the analyte of interest in 
the presence of components that may be expected to be 
present in the sample matrix. 
5.2 Linearity and Range: 
The linearity of an analytical method is its ability to elicit test 
results that are directly (or by a well defined mathematical 
transformation) proportional to the analyte concentration in 
samples within a given range. 9 
5.3 Accuracy 
The accuracy of an analytical method may be defined as the 
closeness of the test results obtained by the method to the 
true value. It is the measure of the exactness of the analytical 
method developed. 10 
5.4  Precision 
The precision of an analytical method is the degree of 
agreement among individual test results when the method is 
applied repeatedly to multiple samplings of homogenous 
samples. This is usually expressed as the standard deviation 
or the relative standard deviation (coefficient of variation). 11 
5.4.1 Determination of Repeatability: Repeatability can be 
defined as the precision of the procedure when 
repeated by same analyst under the same operating 
conditions like same reagents, equipments, settings and 
laboratory over a short interval of time. 12 
5.4.2 Determination of Reproducibility: Reproducibility 
means the precision of the  procedure when it is carried 
out under different conditions, usually in different 
laboratories on separate, putatively identical samples 
taken from the same homogeneous batch of material. 13 
5.5  Limit of Detection and Limit of Quantization 
5.5.1 Limit of Detection: The limit of detection is the 
parameter of limit tests. It is the lowest level of analyte 
that can be detected, but not necessarily determined in 
a quantitative fashion, using a specific method under 
the required experimental conditions. The limit test 
thus merely substantiates that the analyte 
concentration is above or below a certain level. 14 
5.5.2 Limit of Quantitation: Limit of quantitation is a 
parameter of quantitative assays for low levels of 
compounds in sample matrices such as impurities in 
bulk drugs and degradation products in finished 
pharmaceuticals. The limit of quantitation is the lowest 
concentration of analyte in a sample that may be 
determined with acceptable accuracy and precision 
when the required procedure is applied. 15 
5.6  Robustness and Ruggedness 
5.6.1 Robustness: The robustness of an analytical method is 
a measure of its capacity to remain unaffected by small 
but deliberate variation in method parameters and 
provides an indication of its reliability during normal 
usage. The determination of robustness requires that 
methods characteristic are assessed when one or more 
operating parameter varied. 16 
5.6.2 Ruggedness: The ruggedness of an analytical method 
is the degree of reproducibility of test results obtained 
by the analysis of the same samples under a variety of 
normal test conditions such as different laboratories, 
different analysts, using operational and environmental 
conditions that may differ but are still within the 
specified parameters of the assay. 17 
5.7 Stability of Analytical Solution: 
Stability of the sample, standard and reagents is required for 
a reasonable time to generate reproducible and reliable 
results. 18 
5.8  System Suitability:  
System suitability is the checking of a system to ensure 
system performance before or during the analysis of 
unknowns. Parameters such as plate count, tailing factors, 
resolution and reproducibility (% RSD, retention time and 
area for six repetitions) are determined and compared 
against the specifications set for the method. 19 
 
Table 2: System Suitability Parameters and Recommendations20 
Parameters Recommendation 
Capacity Factor (k”) The peak should be well-resolved from other peaks and the void volume, generally K” > 2  
Repeatability  RSD ≤ 1% N ≥ 5 is desirable  
Relative retention  Not essential as the resolution stated  
Resolution (Rs)  
 
Rs of > 2 between the peak of interest and the closest eluting potential interferent (impurity, 
excipients, degradation products, internal standard, etc.)  
Tailing factor (T)  T ≤ 2  
Theoretical plates (N) In general should be > 2000 
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Table 3: Characteristics to be validated in HPLC 21 
Characteristics Acceptance Criteria 
Accuracy / trueness Recovery 98-102% (individual) 
Precision RSD < 2% 
Repeatability RSD < 2% 
Intermediate Precision RSD < 2% 
Specificity/ Selectivity No interference 
Detection Limit  S/N > 2 or 3 
Quantitation Limit S/N > 10 
Linearity Correlation coefficient r2 > 0.999 
Range 80-120% 
Stability >24 h or > 12 h 
 
5.9 Development of Stability indicating HPLC Method 22 
 
Figure 6: Overview of the Method Development Process 
6. CONCLUSION 
The results of the validation study indicate that the analytical 
method developed for the determination of assay is found to 
be accurate and precise. The percentage RSD for all 
parameters was found to be less than two, which indicates 
the validity of the method and assay results obtained bythis 
method are in fair agreement. The method is both repeatable 
and rugged. 
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